-
公开(公告)号：US08026233B2
公开(公告)日：2011-09-27
申请号：US12294550
申请日：2007-03-27
Applicant: Mark C. Munson , Kevin W. Hunt , Christopher T. Clark , Ganghyeok Kim , Laurence E. Burgess , James P. Rizzi
Inventor： Mark C. Munson , Kevin W. Hunt , Christopher T. Clark , Ganghyeok Kim , Laurence E. Burgess , James P. Rizzi
IPC: C07D403/12 , C07D401/12 , A61K31/416
CPC classification number: C07D403/12 , C07D401/12
Abstract: Compounds of formula (I): in which A, B, X, Ar1, R8 and R4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.
Abstract translation: 式（I）化合物：其中A，B，X，Ar 1，R 8和R 4具有本说明书中给出的任何含义，是可用于治疗和预防由p38介导的各种疾病的p38的抑制剂。
-
公开(公告)号：US20110105463A1
公开(公告)日：2011-05-05
申请号：US13001201
申请日：2009-06-24
Applicant: Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff
Inventor： Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff
IPC: A61K31/397 , C07D311/02 , A61K31/352 , C07D405/12 , A61K31/4025 , C07D403/12 , A61K31/453 , A61K31/506 , A61K31/4725 , A61P37/00
CPC classification number: C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
Abstract: Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
Abstract translation: 式（I）化合物：其中A1，A2，W，L，G，R7a，R7b，R8，R9和R10具有本说明书中给出的含义，是可用于治疗免疫疾病的DP2受体调节剂。
-
Patent Agency Ranking
公开(公告)号：US20120101103A1
公开(公告)日：2012-04-26
申请号：US13141675
申请日：2009-12-18
Applicant: Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess
Inventor： Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess
IPC: A61K31/498 , A61K31/497 , A61K31/506 , A61K31/4709 , A61K31/453 , A61K31/444 , A61K31/4433 , A61K31/433 , A61K31/427 , A61K31/428 , A61K31/423 , A61K31/4155 , A61K31/4025 , C07D405/14 , C07D405/12 , C07D417/12 , A61K31/501
CPC classification number: C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12
Abstract: Compounds of Formula I: (I) in which A, A1, R1, R7a, R7b, R8 and R10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D2 (PGD2). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.
Abstract translation: 其中A，A1，R1，R7a，R7b，R8和R10具有本说明书中给出的含义的式I化合物：（I）是可用于治疗和预防免疫疾病的DP2受体抑制剂， 过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎，以及由前列腺素D2（PGD2）介导的其他炎性疾病。 式I化合物还可用于通过产生IL-4，IL-5和/或IL-13来治疗涉及Th2T细胞的疾病或医学病症。
-
公开(公告)号：US20120065195A1
公开(公告)日：2012-03-15
申请号：US13077477
申请日：2011-03-31
Applicant: Christopher T. Clark , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Nicholas C. Kallan , Michael Siu , Allen A. Thomas , Matthew Volgraf
Inventor： Christopher T. Clark , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Nicholas C. Kallan , Michael Siu , Allen A. Thomas , Matthew Volgraf
IPC: A61K31/547 , A61K31/527 , A61K31/4439 , A61K31/423 , A61K31/4184 , C07D279/08 , C07D413/10 , C07D401/14 , C07D263/52 , C07D235/02 , C07D417/10 , A61P25/28 , C07D403/10 , C07D401/10 , C07D491/107 , A61K31/506
CPC classification number: C07D401/14 , C07D263/64 , C07D401/10 , C07D403/10 , C07D413/10 , C07D417/10
Abstract: The invention provides novel spirotetrahydronaphthalene compounds of Formula α that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.
Abstract translation: 本发明提供抑制APP分解酶切割的新颖的式α的四氢四氢化合物，可用作治疗神经变性疾病的治疗剂。
-
公开(公告)号：US08785445B2
公开(公告)日：2014-07-22
申请号：US13141675
申请日：2009-12-18
Applicant: Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess
Inventor： Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess
IPC: C07D405/12 , A61K31/4433 , C07D241/20 , A61K31/497 , A61K31/501 , A61P11/06 , A61P27/14 , A61P17/00 , A61P29/00
CPC classification number: C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12
Abstract: Compounds of Formula I: (I) in which A, A1, R1, R7a, R7b, R8 and R10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D2 (PGD2). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.
Abstract translation: 其中A，A1，R1，R7a，R7b，R8和R10具有本说明书中给出的含义的式I化合物：（I）是可用于治疗和预防免疫疾病的DP2受体抑制剂， 过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎，以及由前列腺素D2（PGD2）介导的其他炎性疾病。 式I化合物还可用于通过产生IL-4，IL-5和/或IL-13来治疗涉及Th2T细胞的疾病或医学病症。
-
公开(公告)号：US08569522B2
公开(公告)日：2013-10-29
申请号：US13001201
申请日：2009-06-24
Applicant: Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff
Inventor： Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff
IPC: C07D311/58 , A61K31/353
CPC classification number: C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
Abstract: Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
Abstract translation: 式（I）化合物：其中A1，A2，W，L，G，R7a，R7b，R8，R9和R10具有本说明书中给出的含义，是可用于治疗免疫疾病的DP2受体调节剂。
-
公开(公告)号：US20090149443A1
公开(公告)日：2009-06-11
申请号：US12294550
申请日：2007-03-27
Applicant: Mark C. Munson , Kevin W. Hunt , Christopher T. Clark , Ganghyeok Kim , Laurence E. Burgess , James P. Rizzi
Inventor： Mark C. Munson , Kevin W. Hunt , Christopher T. Clark , Ganghyeok Kim , Laurence E. Burgess , James P. Rizzi
IPC: A61K31/55 , C07D403/02 , C07D211/32 , A61K31/416 , A61P35/00 , A61K31/4523 , C07D231/56
CPC classification number: C07D403/12 , C07D401/12
Abstract: Compounds of formula (I): in which A, B, X, Ar1, R8 and R4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.
Abstract translation: 式（I）化合物：其中A，B，X，Ar 1，R 8和R 4具有本说明书中给出的任何含义，是可用于治疗和预防由p38介导的各种疾病的p38的抑制剂。
-
-
-
-
-
-
Search Results
7
records
(took 0.022 seconds)
